Soft Tissue Regeneration closed a US $1.5MM Series C Financing and rebranded as Biorez.
At the 2017 AAOS meeting, the company is attending private meetings to share results of a 15-patient safety study that began in 2Q13. Biorez is the first company to clinically investigate a tissue-engineered scaffold for anterior cruciate ligament reconstruction in a human trial.
The investment round was led by Connecticut Innovations, with participation from Vertical Group and KLP Ventures.
Soft Tissue Regeneration closed a US $1.5MM Series C Financing and rebranded as Biorez.
At the 2017 AAOS meeting, the company is attending private meetings to share results of a 15-patient safety study that began in 2Q13. Biorez is the first company to clinically investigate a tissue-engineered scaffold for...
Soft Tissue Regeneration closed a US $1.5MM Series C Financing and rebranded as Biorez.
At the 2017 AAOS meeting, the company is attending private meetings to share results of a 15-patient safety study that began in 2Q13. Biorez is the first company to clinically investigate a tissue-engineered scaffold for anterior cruciate ligament reconstruction in a human trial.
The investment round was led by Connecticut Innovations, with participation from Vertical Group and KLP Ventures.
Copy to clipboard 
